Download Indianapolis/Cincinnati Discussion Group (I/CDG)

An INVITATION to AAPS Indiana/Ohio Discussion Group
(I/ODG) Mini-Symposium Event:
Diagnostics: Challenges/Perspective Symposium
When: 4:00 pm, Wednesday, October 30, 2013
Where: Atherton Union, Reilly Room,
Butler University, 4600 Sunset Avenue, Indianapolis, 46208
Program
Poster/Displays Viewing and Social
Dinner
Seminar Introduction
Seminar (Speaker 1)
Seminar (Speaker 2)
Poster Winners Introduction
Poster Award winners presentation
4:00 - 6:00 PM
6:00 - 6:45 PM
6:55 - 7:00 PM
7:05 - 7:45 PM
7:45 - 8:25 PM
8:25 - 8:30 PM
8:30 - 9:00 PM
(10 minutes each for 3 awardees)
Speaker 1:
Dr. Chitra Edwin, PH, RAC, Director of Regulatory and Quality Affairs,
Cleveland HeartLab, Cleveland, OH.
Topic: “Regulatory aspects of IVDs (in vitro diagnostics; included under
medical devices) and companion diagnostics”
Speaker 2:
Jim S. Strickland, President and Founder, FAST BioMedical Inc.,
Indianapolis, IN.
Topic: “Developing combination products: One company's perspectives”
1
Registration Information
Pre-Registration (‘til October 24th) - $35.00 (mail checks by October 21st)
Students Pre-Registration - $15.00
Late Registration (After October 24th) - $40.00 at door
For more information contact:
Felicia F. Kpakima – Eli Lilly and Co., Phone: 317-651-5658
[email protected]
th
46 Street
Hampton Drive
Sunset
Avenue



Available Parking
Butler University
Gold Sponsor
Bronze Sponsors
2
MEETING REGISTRATION FORM
NAME
_________________________________
INSTITUTION
_________________________________
ADDRESS
_________________________________
_________________________________
TELEPHONE
_________________________________
EMAIL ADDRESS
_________________________________
Please return registration form by fax or e-mail before Thursday, October,
24th.
Payment Options:


By cash or check: please mail the check (payable to AAPS I/ODG) and registration form
Online using PayPal (before October 24th), indicate meal preference via email:
https://sites.google.com/site/aapsiodg/
Felicia F. Kpakima (Attn I/ODG)
Lilly Corporate Center, DC-0724
Indianapolis, Indiana 46285
Phone:317-651-5658
Fax:317-651-6330
Meal Preference (Default meal is vegetarian, if meal preference is unchecked)
____Vegetarian
____Chicken
____Fish
RED CURRY THAI VEGETABLES WITH TOFU
Red Curry Thai Vegetables with Tofu.
MEDITERRANEAN STUFFED CHICKEN
Mediterranean Stuffed Chicken, Fingerling Potato, Grilled Squash.
PESTO SALMON
Pesto Salmon, Red Pepper Basmati Pilaf, Garlic Snow Peas
3
Abstract Submission to I/ODG Mini-Symposium Event:
Diagnostics: Challenges/Perspective Symposium
Deadline: October 18th, 2013
Submission Guideline:
•
•
•
•
•
•
Any topic that fall into the general range of topics (PK/PD and drug metabolism,
design of clinical trials, pharmaceutical science &technology, drug delivery,
toxicology, pharmacology, state of the industry, regulatory affairs, analytical science,
Bio/medical engineering etc.) is in-scope.
Abstract that has been previously presented in other meetings is acceptable. The
meeting where the poster was previously presented should be noted.
Your abstract should be created in Microsoft Word. Please use Times New Roman
10 point font with top and left margins of 1 inch (2.54 cm) and bottom and right
margins of 0.75 inches (1.91 cm). Abstract should include a title, author, and
affiliations followed by abstract itself. The abstract should be no more than 1 page
long. Figures, tables, and symbols are allowed provided that the abstract stays within
the page-length requirements.
Save your abstract as yourfirstname_yourlastname_IODG_poster2013.doc.
All posters will be displayed from 4:00 – 9:00pm (poster set-up begins at 3:30 pm).
Presenting authors must be available for one hour from 5:00 – 6:00pm during
presentation times to answer questions and participate in discussions.
Poster board will be 8ft x 4ft and approximately, 24 Power Points slides (81/2x11in)
will fit comfortably. Push pins will be provided.
Abstract Example:
Metabolism and Disposition of LY2196044, an Opioid Receptor Antagonist, in Humans.
Anthony G. Borel, Ping Yi, Chad Hadden, Robert J. Barbuch, Jennifer Witcher
Department of Drug Disposition. Lilly Research Laboratories, Eli Lilly and Company. Indianapolis, IN
46285.
Correspondence to: Anthony G. Borel Email: [email protected]
Disposition and metabolism of the opioid receptor antagonist LY2196044 in healthy male subjects was
characterized following oral administration of a single 100 mg (100 mCi) solution dose. LY2196044 was
well absorbed, only 2% of unchanged drug appearing in feces; and cleared primarily by metabolism
(~60%), and urinary excretion (~28%). LY2196044 and its major metabolite, M1 (LSN2340637), were the
major circulating species in plasma, accounting for approximately 42% and 19% of systemic exposure
(based on AUC0-), respectively. There were two major metabolic pathways that generally characterized
the 20 identified metabolites – carboxamide hydrolysis to M1 and ethyltetrahydropyran oxidation
accounted for 24% and 18% of the dose, respectively. Of the oxidative metabolites, M29, the most
prominent, is proposed to result from an unusual rearrangement related to oxidation of the
ethyltetrahydropyran to a hemiacetal followed by ring opening and reclosure to form an acetyl substituted
lactam.
I/ODG-AAPS best poster award will be selected for the top three posters
based on scientific content, background, innovation and style. The winners
will have the opportunity to showcase the work as a podium presentation
and be granted an award.
4